Jubilant Epicore LLC
Balance Sheet as at 31 March 2026

	Notes	USD As at 31 March 2026	USD As at 31 March 2025
ASSETS			
Non-current assets			
Intangible assets under development	3	17,943,766	16,109,941
Total non-current assets		**17,943,766**	**16,109,941**
Current assets			
Financial assets			
i. Cash and cash equivalents	4	2,830	42,350
Other current assets	5	139,764	184,204
Total current assets		**142,594**	**226,553**
Total assets		**18,086,360**	**16,336,495**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	6	16,673,575	15,278,575
Other equity		(478,107)	(447,155)
Total Equity		**16,195,468**	**14,831,420**
LIABILITIES			
Current liabilities			
Financial liabilities			
i. Trade payables	7	1,890,892	1,505,075
Total current liabilities		**1,890,892**	**1,505,075**
Total liabilities		**1,890,892**	**1,505,075**
Total equity and liabilities		**18,086,360**	**16,336,495**

Shyam

Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Anuj. Mohnot.

Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Epicore LLC
Statement of Profit and Loss for the year ended 31 March 2026

	Notes	USD For the year ended 31 March 2026	USD For the year ended 31 March 2025
Revenue from operations			
Other income	8	1,141	7,248
Total income		**1,141**	**7,248**
Expenses			
Other expenses	9	32,093	6,039
Total expenses		**32,093**	**6,039**
Loss before exceptional items and tax			
Exceptional items			
(Loss)/ Profit before tax		**(30,952)**	**1,209**
Tax Expenses		-	-
Other comprehensive income			
Items that will not be reclassified to profit or loss			
Changes in fair value of investments which are classified at fair value through OCI		-	-
Items that will be reclassified to profit or loss			
Exchange differences on translation of foreign operations			
Other comprehensive income for the year, net of tax		**-**	**-**
Total comprehensive (loss)/ income for the year		**(30,952)**	**1,209**

Shyam

Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Anuj Mohnot

Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Epicore LLC
Statement of changes in equity for the year ended 31 March 2026

A) Equity share capital

	USD
Balance as at 1 April 2024	**13,683,575**
Additions during the year	1,595,000
Balance as at 31 March 2025	**15,278,575**
Additions during the year	1,395,000
Balance as at 31 March 2026	**16,673,575**

B) Other equity

	Reserves and Surplus	USD
	Retained earnings	**Total**
Balances as at 1 April 2024	**(448,364)**	**(448,364)**
Total comprehensive loss for the year	1,209	1,209
Balances as at 31 March 2025	**(447,155)**	**(447,155)**
Total comprehensive loss for the year	(30,952)	(30,952)
Balances as at 31 March 2026	**(478,107)**	**(478,107)**

Shyam

Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Anuj Mohnot

Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Epicore LLC
Statement of Cash Flows for the year ended 31 March 2025

	USD For the year ended 31 March 2026	USD For the year ended 31 March 2025
A. Cash flow from operating activities		
Profit/(Loss) before tax	**(30,952)**	**1,209**
Operating cash flow before working capital changes	**(30,952)**	**1,209**
(Increase)/ Decrease in trade and other receivables	44,440	(21,496)
(Decrease)/Increase in trade payables, provisions and other liabilities	385,818	402,308
Cash generated from/(used in) operations	**399,306**	**382,021**
Income tax and wealth tax paid (net of refund)		**-**
Net cash generated from/(used in) operating activities	**399,306**	**382,021**
B. Cash flow from investing activities		
Purchase of intangible assets (including capital work-in-progress and intangible asset under development)	(1,833,825)	(1,991,059)
Net cash used in investing activities	**(1,833,825)**	**(1,991,059)**
C. Cash flow arising from financing activities		
Proceeds from issuance of equity	1,395,000	1,595,000
Net cash generated from financing activities	**1,395,000**	**1,595,000**
D. Effect of exchange rate changes		
Net increase in cash and cash equivalents (A+B+C+D)	**(39,519)**	**(14,038)**
Add: cash and cash equivalents at the beginning of year	42,350	56,388
Cash and cash equivalents at the end of the year	**2,831**	**42,350**

Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

1. **Corporate information**

Jubilant Epicore LLC. ("the Company") was incorporated in United States of America under the local laws of Delaware on 19 February 2019. The Company is a fully owned subsidiary of Jubilant Therapeutics India Limited. The Company will focus on the discovery and development of novel drugs for the treatment of cancer in the area of Oncology and Auto-Immune

2. **Significant accounting policies**

This note provides a list of the significant accounting policies adopted in the preparation of these Standalone Financial Statements ("standalone financial statements").

(a) **Basis of preparation**

(i) Statement of compliance

These standalone financial statements have been prepared solely for the purpose of submission of Annual Performance Report to the Reserve Bank of India, in accordance with Indian Accounting Standards (Ind AS) issued by the Institute of Chartered Accountants of India (ICAI).

(ii) Historical cost convention

The Standalone financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is U.S. Dollars ("USD"). These financial statements are presented in USD

(c) **Current versus non-current classification**

The Company presents assets and liabilities in the Standalone Balance Sheet based on current/ non-current classification.

An asset is treated as current when:
- It is expected to be realized or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realized within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

Current assets include the current portion of non-current financial assets.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;

Place: New Jersey

- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified period less than twelve months as its operating cycle for the purpose of current/non-current classification of assets and liabilities.

Jubilant Epicore LLC
Notes to the financial statements for the year ended 31 March 2026

Note 3: Intangible assets under development

	USD	USD
	As at 31 March 2026	**As at 31 March 2025**
Intangible assets under development	17,943,766	16,109,941
Total Intangible assets under development	**17,943,766**	**16,109,941**

Note 4: Cash and cash equivalents

	USD	USD
	As at 31 March 2026	**As at 31 March 2025**
Balances with banks		
In current accounts	2,830	42,350
Total cash and cash equivalents	**2,830**	**42,350**

Note 5: Other current assets

	USD	USD
	As at 31 March 2026	**As at 31 March 2025**
Prepaid expenses	139,764	184,204
Total other current assets	**139,764**	**184,204**

Note 6 : Equity share capital

	USD	USD
	As at 31 March 2026	**As at 31 March 2025**
Issued, subscribed and paid up		
Equity shares	16,673,575	15,278,575

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity share is entitiled to one vote per share.

2) In the event of liquidation of the Company, the holders of shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist

3) The details of shareholders holding more than 5% units in the Company:

		As at 31 March 2026		**As at 31 March 2025**
	No of units	**USD**	**No of units**	**USD**
Name of the Shareholder	100	15,278,575	100	9,033,575
Jubilant Therapeutics Inc	-	1,395,000		2,850,000
	100	**16,673,575**	**100**	**15,278,575**

4) The reconciliation of the numeber of units outstanding as at beginning and at end of the reporting period

Place: New Jersey	**As at 31 March 2026**	**As at 31 March 2025**
	No of units	**No of units**
Numbers of units at the beginning of the year	100	100
Add: Units issued during the year		-
Number of units at the end of the year	**100**	**100**

5) Equity shares held by holding company/ultimate holding company is set out below:

Particulars	**As at 31 March 2026**	**As at 31 March 2025**
Jubilant Therapeutics Inc	100	100

Note 7: Trade payables

	USD	USD
	As at 31 March 2026	**As at 31 March 2025**
Trade payables	269,735	291,274
Due to related parties	1,621,157	1,213,801
Total trade payables	**1,890,892**	**1,505,075**

Jubilant Epicore LLC
Notes to the financial statements for the year ended 31 March 2026

	USD	USD
	31 March 2026	**31 March 2025**
Note 8: Other Income		
Interest income	1,141	2,290
Foreign exchange Gain	0.00	4,958
Total other income	**1,141**	**7,248**

Note 9: Other expenses

	USD	USD
	31 March 2026	**31 March 2025**
Bank charges	6,320	6,039
Foreign exchange gain (Loss)	25,774	
Total other expenses	**32,093**	**6,039**